Preferred Label : Dutasteride;
MeSH definition : A 5-ALPHA-REDUCTASE INHIBITOR that is reported to inhibit both type-1 and type2 isoforms
of the enzyme and is used to treat BENIGN PROSTATIC HYPERPLASIA.;
MeSH synonym : 17beta-N-(2,5-bis(trifluoromethyl))phenyl-carbamoyl-4-aza-5alpha-androst-1-en-3-one;
MeSH hyponym : avodart; GI198745; GG 745; 745, GG; GG-745; GG745;
MeSH Related Number : 164656-23-9;
Wikipedia link : https://en.wikipedia.org/wiki/Dutasteride;
Is substance : O;
UNII : O0J6XJN02I;
Origin ID : D000068538;
UMLS CUI : C0754659;
ATC code(s)
- Allowable qualifiers
- Pharmacological action(s)
- Record concept(s)
- See also inter- (CISMeF)
- Semantic type(s)
- UMLS correspondences (same concept)
- Validated automatic mappings to BTNT
A 5-ALPHA-REDUCTASE INHIBITOR that is reported to inhibit both type-1 and type2 isoforms
of the enzyme and is used to treat BENIGN PROSTATIC HYPERPLASIA.
https://ansm.sante.fr/actualites/retour-dinformation-sur-le-prac-de-mai-2025-5-8-mai
2025
false
false
false
France
French
drug information
risk assessment
Dutasteride
finasteride
suicidal ideation
drug evaluation
---
https://ansm.sante.fr/actualites/reevaluation-europeenne-de-la-balance-benefice-risque-des-medicaments-contenant-du-finasteride-ou-du-dutasteride
2024
false
false
false
France
French
drug information
finasteride
Dutasteride
product surveillance, postmarketing
pharmacovigilance
---
http://www.has-sante.fr/portail/jcms/c_2741821/fr/combodart
http://www.has-sante.fr/portail/jcms/c_2741821/fr/combodart-dutasteride-tamsulosine-inhibiteur-de-la-5-reductase-alpha-bloquant
2016
false
false
false
France
French
evaluation of the transparency committee
guidelines for drug use
drug combinations
administration, oral
adrenergic alpha-1 receptor antagonists
adrenergic alpha-1 receptor antagonists
5-alpha reductase inhibitors
5-alpha reductase inhibitors
Dutasteride
Dutasteride
tamsulosin and dutasteride
prostatic hyperplasia
tamsulosin hydrochloride
tamsulosin hydrochloride
treatment outcome
insurance, health, reimbursement
urinary retention
prostatic hypertrophy, benign
urological agents
urological agents
sulfonamides
sulfonamides
Tamsulosin
Tamsulosin
---
http://www.has-sante.fr/portail/jcms/c_1298559/combodart
http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-09/combodart_05092012_avis_ct9291.pdf
2012
false
France
French
Dutasteride
Dutasteride
Tamsulosin
Tamsulosin
tamsulosin and dutasteride
administration, oral
adult
aged
drug combinations
insurance, health, reimbursement
prostatic hyperplasia
prostatic hyperplasia
sulfonamides
sulfonamides
urinary retention
treatment outcome
clinical trials, phase iii as topic
adrenergic alpha-1 receptor antagonists
adrenergic alpha-1 receptor antagonists
5-alpha reductase inhibitors
5-alpha reductase inhibitors
tamsulosin hydrochloride
tamsulosin hydrochloride
evaluation of the transparency committee
---
http://www.has-sante.fr/portail/jcms/c_1353463/avodart-dutasteride-chibro-proscar-finasteride-combodart-dutasteride-tamsulosine
http://www.has-sante.fr/portail/jcms/c_1353462/avodart-chibro-proscar-combodart-synthese-ct9291-9896-11612-12202
2012
false
France
French
Dutasteride
Dutasteride
administration, oral
insurance, health, reimbursement
dutasteride
tamsulosin and dutasteride
drug combinations
finasteride
finasteride
prostatic hyperplasia
finasteride
5-alpha reductase inhibitors
5-alpha reductase inhibitors
guidelines for drug use
sulfonamides
Tamsulosin
---
https://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2012/13665a-fra.php
2012
false
Canada
French
English
Dutasteride
sulfonamides
risk
administration, oral
prostatic neoplasms
finasteride
5-alpha reductase inhibitors
finasteride
finasteride
dutasteride
tamsulosin and dutasteride
drug combinations
prostatic hyperplasia
alopecia
androgenetic alopecia
pharmacovigilance note
Tamsulosin
---
https://minerva-ebp.be/fr/article/234
2011
false
minerva-ebm.be
Belgium
French
Dutch
critical appraisal or critical reading
Dutasteride
prostatic neoplasms
risk
5-alpha reductase inhibitors
dutasteride
prostatic hyperplasia
treatment outcome
---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=60051234
2008
false
France
French
Dutasteride
Dutasteride
enzyme inhibitors
capsules
administration, oral
drug approval
drug labeling
prostatic hyperplasia
adult
aged
drug interactions
3-Oxo-5-alpha-Steroid 4-Dehydrogenase
drug therapy, combination
enzyme inhibitors
urinary retention
dutasteride
5-alpha reductase inhibitors
5-alpha reductase inhibitors
package leaflet
summary of product characteristics
---
http://www.has-sante.fr/portail/jcms/c_684158/avodart
2008
false
France
French
Dutasteride
administration, oral
enzyme inhibitors
capsules
3-Oxo-5-alpha-Steroid 4-Dehydrogenase
insurance, health, reimbursement
prostatic hyperplasia
urinary retention
dutasteride
5-alpha reductase inhibitors
evaluation of the transparency committee
---
https://www.amub-ulb.be/system/files/rmb/old/158
2005
false
Belgium
French
Dutasteride
enzyme inhibitors
prostatic hyperplasia
5-alpha reductase inhibitors
journal article
---
http://www.has-sante.fr/portail/display.jsp?id=c_399868
2003
false
France
French
Dutasteride
enzyme inhibitors
administration, oral
capsules
3-Oxo-5-alpha-Steroid 4-Dehydrogenase
prostatic hyperplasia
urinary retention
treatment outcome
insurance, health, reimbursement
dutasteride
5-alpha reductase inhibitors
evaluation of the transparency committee
---
